CommercialCoverageMedium impact
Comprehensive Genetic Profiling for Selecting Targeted Cancer Therapies (2.04.115)
Blue Shield of California·CA · Oncology, Hematology, Pathology·Genetic Testing
Effective date
May 1, 2026
We identified it
Feb 1, 2026
Summary
Blue Shield of California updated their genetic profiling policy for cancer treatment, defining specific criteria for when broad molecular profiling and liquid biopsy testing are medically necessary for advanced cancer patients. The policy distinguishes between tumor tissue testing and plasma testing when tissue is insufficient, with comprehensive genetic profiling remaining investigational.
Action Required
Before May 1, 2026: Billing team must review genetic testing claims to ensure they meet new coverage criteria - patients must have recurrent, relapsed, refractory, metastatic, or advanced stage III/IV cancer, and tests must be FDA-approved or CLIA-certified. Update prior authorization processes to verify these requirements. For liquid biopsy claims, ensure tissue-based follow-up is planned if plasma testing yields no results.